Three Kids With Incurable Brain Tumors Are Disease-Free After First-of-Its-Kind Immune-Cell Trial

Some diagnoses come with almost no hope attached. Diffuse intrinsic pontine glioma, known as DIPG, is one of them — a brain cancer so aggressive that most children diagnosed with it don’t survive past two years, and surgery isn’t even an option given where it sits in the brain. So when a small team of doctors quietly tested an entirely new way to fight it, nobody expected a miracle. What they found instead has surprised even seasoned oncologists, and it’s already reshaping how doctors think about treating the deadliest cancers kids can face.

Three Kids Defy the Odds

Doctors at Children’s National Hospital in Washington, DC just shared some genuinely exciting news. In a small trial called ReMIND, four kids with brain cancers that doctors consider incurable are still alive years later. Three of them show no sign of cancer at all. One had a very aggressive tumor type called DIPG, and that child is still alive more than two years after treatment. The other three had tumors that came back after earlier treatment failed. Now, their scans show nothing. In one case, that’s held true for almost five years.

This matters because these weren’t easy cases. Before joining the trial, some kids had already gone through up to 17 rounds of chemotherapy or radiation. They’d run out of standard options.

Dr. Catherine Bollard, one of the lead doctors on the study, said many of these patients “had very few options.” She told New Scientist these cancers are “universally fatal, there’s nothing else for them.” That’s why seeing kids survive this long, with no cancer showing up on their scans, is such a big deal.

So what’s the treatment? It’s a type of therapy that uses the body’s own immune cells, similar in spirit to CAR-T therapy, which has already changed how doctors treat blood cancers. But instead of re-engineering the cells in a lab, doctors took T cells (a type of immune cell) straight from each child’s blood. They exposed those cells to three proteins commonly found on these tumors, then grew the cells that reacted best. No lab-engineered genes involved — just the child’s own immune system, boosted and redirected.

How the Treatment Actually Works

Now let’s get into what makes this therapy different from other cell therapies you may have heard about.

Doctors start by drawing blood from the child. From that blood, they pull out white blood cells and grow special cells called dendritic cells, which act like teachers for the immune system. These dendritic cells get loaded with pieces of the three tumor proteins mentioned earlier — WT1, PRAME, and survivin. Then, the child’s own T cells (the immune system’s attack cells) are introduced to these loaded dendritic cells. Whichever T cells recognize the tumor proteins and react get pulled aside and multiplied in the lab until there are enough to send back into the child’s body.

Here’s the key difference from CAR-T therapy: there’s no genetic engineering involved. CAR-T cells are modified in a lab to carry an artificial receptor. TAA-T cells, the kind used in this trial, rely on the T cells’ own natural receptors. That matters because these natural receptors can detect even small amounts of the target proteins on tumor cells, while CAR-T cells often need higher amounts to work.

The delivery method is different too. These cells go into the bloodstream through a simple IV, not injected directly into the brain or spinal fluid. That’s a much easier and lower-risk process for a child to go through. It may also help the treatment interact with the immune system more broadly throughout the body, not just at the tumor site.

As Dr. Eugene Hwang, one of the study’s co-senior authors, explained: “We were excited to see that we could preserve safety and quality of life while generating anti-tumor responses by attacking three targets at once.”

Inside the Trial: The Numbers and the Safety Data

This was a phase 1 trial, which means the main goal was to check whether the treatment was safe — not to prove it works. That’s an important distinction. Bigger trials focused on effectiveness would need to come next.

A total of 33 patients received the treatment. Eleven had DIPG. Eighteen had a recurrent tumor outside the brainstem. Four more had a recurrent tumor and also received a short round of chemotherapy beforehand to weaken their immune system, a step sometimes used to help cell therapies work better.

The good news: treatment was generally well tolerated. Most side effects were mild, with fatigue and headache topping the list. That’s a relatively gentle safety profile compared to some other cell therapies, which can trigger much rougher reactions.

Now for the standout results within that group of 33. One child with DIPG is still alive more than two years after treatment. Among the kids with recurrent tumors, three had exceptional outcomes. One child, previously diagnosed with a rare brain tumor, reached a complete response and has stayed cancer-free for three years. Two others remain disease-free more than two and four years out, respectively, without needing any further treatment. Keep in mind: these were kids who’d already been through as many as 17 rounds of chemotherapy or radiation before joining the trial.

Dr. Bollard shared a personal note about staying in touch with one of the families: “They’re unbelievably grateful that their child is still with them today.”

Two more phase 1 trials testing this same approach are already underway, which means researchers are moving quickly to build on what they’ve learned here.

Limitations and What This Means Going Forward

Before getting too excited, it’s worth being upfront about the tougher parts of this trial too, because a balanced picture matters here.

Not everyone in the trial did well. Tragically, one child with DIPG died after developing dangerous swelling around the tumor, along with fluid buildup in the brain and breathing failure, about 10 days after treatment. Doctors classified this as a dose-limiting toxicity, meaning it directly shaped how the trial moved forward. After this happened, the research team paused enrollment and tightened the eligibility rules, requiring kids to be more neurologically stable before receiving treatment. Another child had a serious but reversible reaction involving brain swelling, which resolved once treated with medication.

It’s also worth noting: most kids in the recurrent-tumor group had already gone through several rounds of prior treatment, and some pursued additional therapies afterward. That makes it hard to say with certainty how much of their survival came from this treatment alone versus everything else they’d already tried. This trial also wasn’t designed or sized to prove the therapy works — only to check that it’s safe and can be manufactured reliably. Those goals were met, but bigger studies are still needed before this becomes a standard option.

Even with those caveats, this is genuinely good news. Doctors are already testing this same approach in two follow-up trials, one pairing it with a technique to help the treatment reach deeper into the brain, and another applying the same method to a different set of tumors and targets.

For families facing a DIPG or recurrent brain tumor diagnosis, options have historically been almost nonexistent. This trial doesn’t change that overnight. But it shows a real, working path forward, and for a disease this brutal, that’s worth taking seriously.

Here’s the updated section with new products swapped in:

My Personal RX on Giving Your Immune System (and Brain) Some Backup

What strikes me most about this trial isn’t just the technology. It’s that the real hero here is the immune system itself. Doctors simply gave it a boost and pointed it in the right direction. Most of us will never need a treatment this advanced, but we can all support our immune system and brain health every single day. And when scary health news hits close to home, taking care of your own body helps you show up for the people who need you. Here are 10 habits I recommend to patients, straight from years of practicing medicine.

1. Protect your sleep: Deep sleep is when your immune cells repair and regroup. Magnesium helps calm your nervous system and relax your muscles, which can support deeper rest. Magnesium Essentials is worth considering if you’re not getting enough through diet alone.
2. Eat the rainbow: Colorful fruits and vegetables are packed with antioxidants that protect your cells from damage.
3. Move every day: A 30-minute walk boosts circulation and helps immune cells patrol your body more effectively.
4. Feed your brain healthy fats: Fatty fish twice a week is ideal. If that’s not realistic for you, an Omega-3 Fish Oilsupplement is a solid backup for both brain and heart health.
5. Support your immune defenses:Vitamin D plays a major role in keeping your immune system sharp, and pairing it with vitamin K2 helps direct calcium to your bones instead of your arteries. Vitamin K2 with D3 covers both in one supplement.
6. Manage stress on purpose: Chronic stress can weaken your immune response over time. Even five minutes of deep breathing daily makes a difference.
7. Stay hydrated: Water supports every organ system, including the ones fighting off illness.
8. Don’t skip your checkups: Early detection saves lives. Regular screenings catch problems before symptoms even show up.
9. Lean on your people: Strong relationships genuinely buffer stress and build resilience for hard times.
10. Be gentle with yourself: If a diagnosis, yours or a loved one’s, has you scared, that’s normal. Reach out to your doctor or a mental health professional when you need support. You don’t have to carry it alone.

Source:

1. Kang, J. M., Han, E. H., Choi, J.-K., Youm, S., Pareek, T., Levi, L., Kim, S.-J., Letterio, J., & Lim, S. (2026). The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice. Nature Communications, 17(1). https://doi.org/10.1038/s41467-026-74891-3
2. Simmons, L. (2026, July 23). Three Kids With Incurable Brain Tumors Have No Evidence Of Disease Thanks To Breakthrough, First-Of-Its-Kind Clinical Trial. IFLScience. https://www.iflscience.com/three-kids-with-incurable-brain-tumors-have-no-evidence-of-disease-thanks-to-breakthrough-first-of-its-kind-clinical-trial-84186